Piper Sandler Maintains Buy Rating on Natera, Adjusts Price Target
Piper Sandler has reaffirmed its 'Buy' rating on Natera, Inc. while revising its price target for the company's stock to $350.
Stocks · News reference
Natera, Inc. has agreed to pay $375,000 to the state of California to resolve allegations regarding missed pay data report deadlines for the years 2022 through 2025.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Piper Sandler has reaffirmed its 'Buy' rating on Natera, Inc. while revising its price target for the company's stock to $350.
Natera, Inc. received the 'Best in Class' award in the Cancer, Screening & Early Detection category at the 2026 Digital Health Hub Foundation Digital Health & AI Awards.
CNBC traders picked Micron, Digital Realty, Natera and Moody’s; Natera raised FY2026 sales guidance after strong results, while Moody’s missed estimates.
Natera, Inc. has entered into a clinical collaboration agreement with Incyte to evaluate the investigational bispecific immunotherapy INCA33890 in a new Phase II study for colorectal cancer patients.
Analyst Max Masucci of Roth MKM maintained a 'Buy' rating on Natera, Inc. while adjusting the price target to $405.